کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5630255 | 1580372 | 2017 | 9 صفحه PDF | دانلود رایگان |
- Dopamine receptor D3 signaling reduces antigen cross-presentation in dendritic cells.
- Dopamine receptor D3 antagonism in dendritic cells increases CD8+ T-cells response.
- Dopamine receptor D3 deficiency in dendritic cells strengthens anti-tumor immunity.
Dendritic cells (DCs) display the unique ability for cross-presenting antigens to CD8+ T-cells, promoting their differentiation into cytotoxic T-lymphocytes (CTLs), which play a pivotal role in anti-tumor immunity. Emerging evidence points to dopamine receptor D3 (D3R) as a key regulator of immunity. Accordingly, we studied how D3R regulates DCs function in anti-tumor immunity. The results show that D3R-deficiency in DCs enhanced expansion of CTLs in vivo and induced stronger anti-tumor immunity. Co-culture experiments indicated that D3R-inhibition in DCs potentiated antigen cross-presentation and CTLs activation. Our findings suggest that D3R in DCs constitutes a new therapeutic target to strengthen anti-tumor immunity.
147
Journal: Journal of Neuroimmunology - Volume 303, 15 February 2017, Pages 99-107